Anti-Pneumocystis Activities of Aromatic Diamidoxime Prodrugs by Hall, James Edwin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY,
0066-4804/98/$04.0010
Mar. 1998, p. 666–674 Vol. 42, No. 3
Copyright © 1998, American Society for Microbiology
Anti-Pneumocystis Activities of Aromatic Diamidoxime Prodrugs
JAMES EDWIN HALL,1,2 JOHN E. KERRIGAN,2† KISHORE RAMACHANDRAN,2
BRENDAN C. BENDER,2 JASON P. STANKO,2 SUSAN K. JONES,2
DONALD A. PATRICK,2 AND RICHARD R. TIDWELL2,3*
Departments of Epidemiology,1 Pathology,2 and Medicinal Chemistry,3
University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina 27599
Received 29 May 1997/Returned for modification 19 September 1997/Accepted 22 December 1997
Aromatic dicationic compounds, such as pentamidine, have potent antimicrobial activities. Clinical use of
these compounds has been restricted, however, by their toxicity and limited oral activity. A novel approach,
using amidoxime derivatives as prodrugs, has recently been proposed to overcome these limitations. Although
results were presented for amidoxime derivatives of only one diamidine, pentamidine, the authors in the
original proposal claimed that amidoxime derivatives would work as effective prodrugs for all pharmacolog-
ically active diamidines. Nine novel amidoxime derivatives were synthesized and tested in the present study for
activity against Pneumocystis carinii in corticosteroid-suppressed rats. Only three of the nine compounds had
significant oral anti-Pneumocystis activity. The bisbenzamidoxime derivatives of three direct pentamidine
analogs had excellent oral and intravenous activities and reduced acute host toxicity. These compounds are not
likely candidates for future drug development, however, because they have chronic toxic effects and the active
amidine compounds have multiple sites susceptible to oxidative metabolism, which complicates their phar-
macology and toxicology. Novel diamidoximes from three other structural classes, containing different groups
linking the cationic moieties, lacked significant oral or intravenous anti-Pneumocystis activity, even though the
corresponding diamidines were very active intravenously. Both active and inactive amidoximes were readily
metabolized to the corresponding amidines by cell-free liver homogenates. Thus, the amidoxime prodrug
approach may provide a strategy to exploit the potent antimicrobial and other pharmacological activities of
selected, but certainly not all, aromatic diamidines.
Aromatic dicationic compounds, including bisbenzamidines
and dicationically substituted bisbenzimidazoles and carba-
zoles, have excellent experimental anti-Pneumocystis activities
(14, 40, 46, 48, 50, 51) and are also active against other micro-
bial pathogens, including protozoan parasites (2–5, 10, 38, 41,
43, 44), fungi (45), and some viruses (25–27, 49, 53). Aromatic
dications also possess other pharmacological properties, in-
cluding antiinflammatory and anticoagulant activities (29–37).
Two problems hindering development of these compounds as
new drugs, however, are limited oral bioavailability and toxicity
(24, 38, 48, 51).
Recent studies of pentamidine metabolism (7–9, 21–23)
have led to a novel approach to overcome the limited oral
bioavailability and acute toxicity. Aromatic diamidoximes are
hypothesized to be orally bioavailable prodrugs that are readily
reduced by drug-metabolizing enzymes to the active aromatic
amidines (19, 21, 22), resulting in excellent antimicrobial ac-
tivity with reduced acute host toxicity.
Amidoximes were first shown by Lamb and White to be
active against experimental African trypanosomiasis (42) and
then later were shown to be active against other microorgan-
isms (1, 17, 18, 28). Although activities were often reported for
both amidoximes and corresponding amidines, no mention was
made in these early publications that metabolic activation was
required for in vivo activity of the amidoximes. Moreover, no
systematic studies were performed to determine which analogs
were orally active and if the amidoxime derivatives had in-
creased oral activity compared to the amidines. Thus, the con-
cept of amidoximes as prodrugs of amidines was not raised in
earlier studies.
The hypothesis that amidoximes might be useful prodrugs
resulted from research examining the metabolism of pentam-
idine (6–9, 21, 22). Two primary oxidative metabolites identi-
fied were the mono- and diamidoximes, formed by N-hydroxy-
lation of pentamidine. Although the diamidoxime derivative of
pentamidine has little or no activity against three protozoan
parasites in vitro, both the mono- and diamidoximes were active
against African trypanosomes and Leishmania spp. when given
to experimental animals subcutaneously (19, 21–23, 39). The
diamidoxime given orally to rats was absorbed from the gut
and converted to pentamidine, a reaction subsequently shown
to be catalyzed by an oxygen-independent hepatic reductase
activity (21, 22). These observations led to the proposal that
amidoxime derivatives, in general, are effective, orally ab-
sorbed prodrugs for all pharmacologically active amidine-con-
taining compounds (19). However, the only amidoximes tested
were derivatives of pentamidine. We recently demonstrated
that two novel amidoximes of 2,5-bis[4-amidinophenyl]furan
were highly active orally and intravenously (13). Moreover,
Weller and coworkers demonstrated that amidoximes of po-
tent monoamidine fibrinogen receptor antagonists greatly en-
hanced their oral bioavailability (54).
With this promising background, we began to synthesize
potential amidoxime prodrugs of our most active, least toxic
diamidines. Results presented here, however, demonstrate that
amidoximes are not effective prodrugs for all aromatic dica-
tionic compounds. The nature of the linker between the two
amidoxime moieties plays a key role in determining if a par-
ticular diamidoxime has oral anti-Pneumocystis activity. Di-
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amidoxime derivatives of the very promising bisbenzimidazole
and carbazole classes of dications, and bisbenzamidoximes that
contain additional nitrogen atoms in the aliphatic linkers, had
little or no anti-Pneumocystis activity, even though the parent
diamidines had excellent intravenous activity. Variability in
activity does not appear to be caused by differences in enzy-
matic reductase activity, since both active and inactive diami-
doximes were metabolized by cell-free liver homogenates.
MATERIALS AND METHODS
Synthesis of compounds. The known diamidine compounds tested in this study
were synthesized in our laboratory by previously described methods (7, 40, 48,
51). The novel diamidines 12, 14, 18, and 19 (Table 1) were prepared by similar
methods. The known di- and monoamidoximes (compounds 1 and 9 [Table 1]) of
pentamidine were prepared according to the procedures of Clement and Raether
(23). All novel amidoximes were prepared by similar procedures, with the ex-
ception of compound 19, which was prepared by a Pinner synthesis from the
corresponding dinitriles. Each compound was characterized by high-perfor-
mance liquid chromatography (HPLC), elemental analysis, high-resolution fast
atom bombardment mass spectrometry, and proton magnetic resonance. Struc-
tures of test compounds are shown in Table 1, and the melting points and
elemental analyses for the novel compounds are given in Table 2.
Anti-Pneumocystis activity. The induction and treatment of Pneumocystis pneu-
monia in the rat model were carried out according to published methods (40, 50,
51). Adult male Sprague-Dawley rats, barrier raised, not certified virus free, and
weighing 150 to 200 g, were obtained from Hilltop Laboratories (Scottdale, Pa.).
The individually caged animals were begun immediately upon arrival on an
immunosuppressive regimen consisting of a low-protein (8%) diet (Zeigler
Brothers, Gardner, Pa.) and drinking water containing tetracycline (0.5 mg/ml)
and dexamethasone (1.0 mg/ml). This regimen was continued for the next 8
weeks, with animals monitored daily and weighed weekly. At the beginning of the
7th week, animals were divided into groups of at least six animals per group and
the test compounds were administered daily for 14 days either orally by gavage
or intravenously by tail vein injection. Compounds were routinely tested orally at
33 mmol kg of body weight21 day21 and intravenously at 22 mmol kg of body
weight21 day21. Saline- and pentamidine-treated groups were included as neg-
ative and positive controls, respectively.
All animals were sacrificed at the end of the 8th week by chloroform inhala-
tion. The left lung was excised, placed in cold Hanks balanced salts minus Ca21
and Mg21 (HBSS2), then weighed, ground through a no. 60 wire mesh screen,
and suspended 1:10 (wt/vol) in 10 mM b-mercaptoethanol in HBSS2. Slides were
prepared by spotting 5 ml of lung homogenate and were allowed to air dry. Slides
were treated with acid and stained with cresyl violet (11), and the cysts were
counted by using a blinded protocol. The number of cysts per gram of original
lung tissue was calculated, and the values for groups were reported as percent-
ages of values for saline-treated controls (51).
In vivo toxicities of test compounds. Preliminary evaluations of relative toxic-
ities of test compounds were performed in two ways. First, the dexamethasone-
immunosuppressed test rats were closely observed throughout the 14 days of
intravenous or oral administration for overt toxic responses. Animals were ob-
served closely for a 10- to 15-min period following injection of the test drug each
day for signs of acute toxicity, including the hypotensive response (paling of eyes
and paws, dyspnea, lethargy, and decreased body temperature) elicited by intra-
venous pentamidine at its effective dose. Their overall health and general well-
being were observed and recorded on a daily basis for the remainder of the
experiment. Excessive weight loss (more than a twofold loss compared to the
saline controls over the 2-week dosing period) was considered a key indicator of
declining health due to drug toxicity. At necropsy, the liver, spleen, kidneys, and
pancreas were removed from each animal and examined for gross pathology.
Subjective scores (40, 51) of toxicity associated with multiple dosing were as-
signed to each compound (Table 1) and are discussed further in Results and
Discussion.
The second method used to evaluate relative toxicities of test compounds was
to perform preliminary dose escalation studies with rats that were not immuno-
suppressed by dexamethasone treatment. Adult male Sprague-Dawley rats, bar-
rier raised, not certified virus free, and weighing 300 to 450 g at the time of
testing were obtained from Hilltop Laboratories. The individually caged animals
were given water and standard rat chow (Agway, Syracuse, N.Y.) ad libitum.
Each animal was injected via the tail vein with one dose of test compound. Each
animal was closely observed for 15 min postinjection, especially for signs of
hypotension elicited by pentamidine, as described above, and was monitored
again at 30 min, 60 min, and 24 h postinjection.
In vitro metabolism. In vitro metabolism of diamidoximes by rat liver homog-
enate 9,000 3 g supernatants, postmitochondrial 105,000 3 g supernatants, or
microsomal fractions was performed as previously described (8, 9). Briefly, adult
male barrier-raised Sprague Dawley rats (Hilltop Laboratories) were allowed
free access to rat chow (22.5% protein, 5.5% fat, and 4.5% fiber, with essential
vitamins and minerals; Agway) and tap water. Rats were euthanized by decapi-
tation, and the livers were removed immediately, rinsed with 50 mM potassium
phosphate buffer (pH 7.4), and placed on ice. All subsequent steps were per-
formed at 4°C. The livers were minced and homogenized, and 9,000 3 g super-
natants, 105,000 3 g supernatants, or 105,000 3 g microsomal pellets were
prepared as described elsewhere (6). Each fraction was assayed for protein
content (15) and stored at 280°C. Fractions from rat kidneys, lungs, hearts, and
brains were prepared in a similar fashion, as previously described (8, 9).
Reaction mixtures for all cell-free homogenates consisted of 1.5 ml of 50 mM
potassium phosphate buffer (pH 7.4), 0.5 ml of cofactor solution (2 mg of
NADPH/ml, 1.6 mg of MgCl2/ml, 1.04 mg of glucose-6-phosphate/ml, and 2 U of
glucose-6-phosphate dehydrogenase/ml in 50 mM potassium phosphate buffer
[pH 7.4]), 0.5 ml of tissue homogenate, and 0.5 ml of the appropriate substrate
at concentrations shown in the figure legends. Reactions were started by adding
substrate; then mixtures were incubated at 37°C in a shaking water bath for times
shown in the figure legends. Reactions were terminated by extraction over C18
cartridges, and extracts were assayed as described below.
Metabolic experiments with intact cultured cells were routinely performed
with the BRL 3A hepatocyte line, obtained from the Lineberger Tissue Culture
Facility of the University of North Carolina at Chapel Hill. Cells were cultured
in Costar (Cambridge, Mass.) 25-cm2 tissue culture flasks at 37°C under a moist
atmosphere of 5% CO2 and 95% air in Ham’s F-12 medium (Gibco BRL,
Gaithersburg, Md.) containing 5% fetal bovine serum (HyClone Laboratories,
Inc., Logan, Utah). Confluent cultures were treated with 0.25% trypsin solution
(Sigma Chemical Co., St. Louis, Mo.), and then approximately 2 3 105 cells/well
were subcultured into Costar 6-well tissue culture chambers and the cells were
allowed to grow to confluency. Fresh medium (10 ml) was added to each culture
well, and incubations were started by adding 100 ml of amidoxime stock solution,
prepared in sterile water, to a final concentration of 10 mM. Cell cultures were
incubated at 37°C under a moist atmosphere of 5% CO2 and 95% air for 24 h,
and then aliquots of culture supernatants were extracted and assayed for metab-
olites as described below. Similar metabolic experiments were performed with
cultured J774 A.1 mouse monocyte-macrophage cells cultured in Dulbecco mod-
ified Eagle F-12 medium containing 10% fetal bovine serum and H9c2 rat heart
myoblast cells cultured in Dulbecco modified Eagle H medium containing 10%
fetal bovine serum.
Samples were extracted by solid-phase extraction and were assayed by HPLC
by methods similar to those previously described (8, 9). Briefly, samples spiked
with 2,5-bis[4-(N-isopropylamidino)phenyl]furan dihydrochloride as the internal
standard were extracted over activated C18 Bond Elut cartridges (Varian Asso-
ciates, Sunnydale, Calif.), washed with water, and eluted first with 100% aceto-
nitrile and then with 75% acetonitrile–25% water containing 15 mM triethyl-
amine and 35 mM acetic acid. The diamidoxime substrates elute in the 100%
acetonitrile phase, while mono- and diamidine products elute in the acetonitrile-
water mix containing triethylamine and acetic acid. Eluates were evaporated to
dryness at 40°C under a gentle stream of nitrogen and were resuspended in 10%
acetonitrile in HPLC-grade water.
Compounds were resolved by using a Hewlett-Packard (Avondale, Pa.) model
1090 HPLC equipped with an HP 1050 variable wavelength detector, a 4.6- by
250-mm Zorbax RX diisopropyl C8 column (Mac-Mod, Chadd’s Ford, Pa.)
maintained at 40°C, and a Vectra 486/66U computer with HP ChemStation
software. The mobile phase consisted of 15 mM triethylamine and 35 mM acetic
acid in HPLC-grade water for pump A, and 15 mM triethylamine and 35 mM
acetic acid in 75% aqueous acetonitrile in water for pump B. The solvent flow
rate was 1.5 ml/min, and the solvent gradient ran from 0% B to 25% B at 22 min,
to 40% B at 25 min, and then to 90% B at 35 min, followed by a 5-min recycle
period. All solvents and reagents used for the assays were HPLC grade. For
quantitative experiments, amounts of metabolites formed were calculated, by
using peak area ratios of authentic standard to internal standard, from standard
addition curves generated by spiking standards into tissue homogenates or tissue
culture medium.
RESULTS AND DISCUSSION
Anti-Pneumocystis activities of bisbenzamidoximes. A major
limitation of aromatic dicationic compounds as antimicrobial
agents has been their lack of oral activity. Results from the
present study demonstrate that four bisbenzamidoximes, dia-
midoxime derivatives of pentamidine and three novel direct
pentamidine analogs, have excellent oral anti-Pneumocystis ac-
tivities in the immunosuppressed-rat model of disease. Com-
pound structures and anti-Pneumocystis activities of these bis-
benzamidoximes and their corresponding bisbenzamidines are
given in Table 1.
In agreement with previous results (19), the diamidoxime
derivative (compound 1) of pentamidine had significant anti-
Pneumocystis activity when given orally by gavage at 33 mmol
kg21 day21, compared to the oral saline control group (Table
1). The novel bisbenzamidoxime compounds 3, 5, and 7 were
even more active, with the lowest cyst scores reported to date
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TABLE 1. Anti-Pneumocystis activities of novel amidoximes and corresponding amidines
Compound no. Structure
Oral dosinga i.v. dosingb
mmol/kg Toxicitye % Saline control
c
6 SE mmol/kg Toxicity
e % Saline controld
6 SE
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from our laboratories for orally administered aromatic dica-
tionic compounds (40, 48, 51).
In contrast, the corresponding diamidines were less active
when given orally (Table 1). Pentamidine (compound 2) was
completely inactive at the oral daily dose of 33 mmol kg21 for
14 days. Cyst scres for diamidine compounds 4 and 6 were
slightly, but not significantly, reduced compared to the oral
saline controls. Cyst counts were more than 15-fold higher for
these diamidines than for their corresponding diamidoximes,
compounds 3 and 5 (Table 1). The only diamidine compound
with good oral activity was compound 8. Its diamidoxime an-
alog, compound 7, had a slightly lower mean cyst score.
Each of the bisbenzamidoxime compounds 1, 3, 5, and 7 also
had excellent anti-Pneumocystis activity when given intrave-
nously at 22 mmol kg21 once daily for 14 days (Table 1). Mean
cyst counts were greatly reduced compared to those for the
saline controls and were also significantly lower than the mean
count for the intravenous pentamidine (compound 2) control
group. The diamidine compounds 4, 6, and 8 have previously
been shown to have intravenous activity (40, 48; Table 1).
Direct comparisons of intravenous anti-Pneumocystis activities
of these diamidines to those of the corresponding diami-
doximes, compounds 3, 5, and 7, cannot be made because the
intravenous activities of diamidines were previously evaluated
by a different cyst score method and at slightly different doses.
Subjectively, however, diamidoximes do appear to compare
favorably with the corresponding diamidines with regard to
intravenous efficacy.
Anti-Pneumocystis activities of monobenzamidoximes. Sub-
stitution of amidoxime moieties for both dicationic groups may
be required for oral but not for intravenous anti-Pneumocystis
activity. Two mono-substituted amidoximes were synthesized
and tested (Table 1). Compound 9, the monoamidoxime ana-
log of pentamidine, was significantly active at an intravenous
dose of 22 mmol kg21 day21. The compound was inactive at an
oral dose of 33 mmol kg21 day21, however. A second mono-
amidoxime, compound 10, which contains one amidoxime moi-
ety and one imidazoline cationic group, was active intrave-
nously at a dose of 10 mmol kg21 day21 but was not active
when given orally at the high dose of 58 mmol kg21 day21.
Thus, both cationic moieties apparently must be in the ami-
doxime form for oral uptake to occur.
Diamidoximes that lack activity against Pneumocystis. Not
all diamidoxime compounds have improved antimicrobial ac-
tivity compared to the diamidine analogs, indicating that the
prodrug approach will not work for all classes of aromatic
dicationic compounds. The potent antitrypanosomal diamidine
compound, diminazine (Berenil), has excellent in vivo activity
against African trypanosomes and Leishmania; its diami-
doxime derivative, however, was only marginally active when
given subcutaneously (20). Diminazine has a triazine bridge
connecting the benzamidino moieties. Our current results in-
dicate that diamidoximes from three other classes of com-
pounds lack oral and intravenous activity against Pneumocystis.
These diamidoximes, like the diamidoxime of diminazine, also
have nitrogen atoms in positions other than the amidoxime
moieties and lack the ether oxygens in the bridge between
aromatic groups.
(i) Bisbenzamidoximes that lack anti-Pneumocystis activity.
Two novel bisbenzamidine compounds (compound 12 and 14)
(Table 1), each containing internal amide groups as part of the
bridge linking the benzamidine moieties, were synthesized and
tested for activity against Pneumocystis. The compounds were
synthesized because they were hypothesized to have improved
DNA binding properties, increased aqueous solubility, and
reduced metabolism along the cleavage pathways that have







Elemental analysis (calculated/found [%])
C H N
3 C18H22N4O4 z 2C4H4O4 154 359.1719/359.1762 ND
a ND ND
5 C17H20N4O4 z 2C4H4O4 158–159 ND 52.08/52.15 4.90/4.95 9.72/9.68
7 C27H32N4O14 z H2O 134 405.1774/405.1795 49.53/49.54 5.24/5.31 8.56/8.40
10 C21H26N4O3 z HCl z O.8H2O 196–198 ND 58.21/57.99 6.65/6.55 12.93/13.29
11 C18H20N6O4 z 2C4H4O4 207–208 385.1624/385.1604 50.65/50.51 4.58/4.68 13.63/13.38
12 C18H20N6O2 z 2HCl z 0.4H2O .300 353.1725/353.1752 49.99/50.24 5.31/5.54 19.43/19.09
13 C17H18N6O4 z 2C4H4O4 159–161 371.1467/371.1461 49.84/49.67 4.35/4.44 13.95/14.20
14 C17H18N6O2 z 2HCl .300 339.1569/339.1552 49.65/49.74 4.90/4.95 20.43/20.33
15 C20H22N8O2 z 2HCl 284–287 407.1957/407.1956 59.10/58.88 5.46/5.57 27.57/27.35
17 C22H26N8O2 z 2C4H4O4 145–147 435.2256/435.2245 54.05/53.93 5.14/5.34 16.81/16.70
18 C22H26N8 z 2HCl z 1.7H2O 280–282 403.2358/403.2369 52.22/52.30 6.25/6.15 22.14/21.99
19 C14H13N5O2 z 2C4H4O4 .300 284.1148/284.1141 51.27/50.51 4.11/4.14 13.59/12.50
a ND, not done.
a Each compound was given by gavage to at least six rats once daily for 14 days. One rat dosed with compound 3, one dosed with compound 5, and one dosed with
compound 18 died (on days 13, 7, and 11, respectively) during treatment.
b Each compound was given via tail vein injection to at least six rats once daily for 14 days. Three rats died during treatment with compound 7, and three died during
treatment with compound 18. i.v., intravenous.
c Cysts per gram of lung were 37.7 3 106 for the oral saline control group (n 5 6).
d Cysts per gram of lung were 44.7 3 106 (n 5 65) for the i.v. saline control group and 0.9 3 106 (n 5 64) for the i.v. pentamidine group.
e Toxicity scores are subjective evaluations of overt toxicity in dexamethasone-immunosuppressed rats. Scores of 0 indicate no observable deleterious effects from
dosing, whereas 111, the highest score assigned to these compounds, indicates death of approximately 50% of the group. See the text for a more complete description.
f Significantly different from appropriate saline control group; P , 0.05 (Student’s t test).
g Significantly different from i.v. pentamidine group; P , 0.05 (Student’s t test).
h Numbers in brackets are histologic scores determined subjectively from cysts detected in stained lung sections. Scores range from the lowest possible score of 0.5
to the highest of 4.0. Data reprinted from the Journal of Medicinal Chemistry (50).
i Tested at a lower dose due to insufficient quantities available.
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been proposed to decrease the activity and increase the toxicity
of pentamidine. Both diamidines had significant anti-Pneumo-
cystis activity when administered at 22 mmol kg21 day21 intra-
venously. The diamidoxime derivatives (compounds 11 and 13)
of each compound, however, were not active, either intrave-
nously (22 mmol kg21 day21) or orally (33 mmol kg21 day21)
(Table 1).
(ii) Bisbenzimidazole and carbazole diamidoximes that lack
anti-Pneumocystis activity. Dicationically substituted bisben-
zimidazoles have excellent activity against Pneumocystis, with
selected compounds showing marked improvements in toxicity
and pharmacologic properties compared to pentamidine (51).
However, oral bioavailability for these compounds also ap-
pears to be limited. To determine if the prodrug approach
could be used for this class of aromatic dications, we synthe-
sized and tested the diamidoxime derivative (compound 15)
(Table 1) of one of our most active bisbenzimidazole diami-
dines (compound 16). Although the diamidine has been shown
to have excellent anti-Pneumocystis activity at 18 mmol kg21
day21 intravenously, the diamidoxime was completely inactive
intravenously and orally (Table 1). One other bisbenzimida-
zole diamidoxime, in which the benzimidazole nitrogen was
substituted with a methyl group (compound 17) (Table 2), was
synthesized and tested. The diamidine analog (compound 18)
had excellent intravenous activity at 22 mmol kg21 day21. The
diamidoxime, however, lacked significant intravenous and oral
activity (Table 1).
Finally, a new series of aromatic dicationic compounds con-
taining a carbazole nucleus linking the dications have been
synthesized. Several members of this class, most notably com-
pound 20 (Table 1), have been shown to have superb activity
against Pneumocystis carinii and Cryptosporidium parvum in
vivo and are also active against several other opportunistic
pathogens in vitro (47). The diamidoxime 19 was synthesized
as a potential prodrug of compound 20 to increase its oral
bioavailability. However, compound 19 was inactive when
given orally at 33 mmol kg21 day21 (Table 1).
Toxicity of bisbenzamidoximes. A second major factor lim-
iting development of aromatic dications as antimicrobial drugs
has been toxicity. We report here preliminary observations of
acute and subchronic toxicity in rats treated intravenously and
orally with three bisbenzamidoximes active against Pneumocys-
tis. Although the toxicity information presented is mainly an-
ecdotal and should not be considered definitive, these evalua-
tions do permit important preliminary comparisons of relative
toxicities of compounds.
(i) Acute toxicity in nonimmunosuppressed rats. A prelim-
inary dose escalation study was performed with non-dexa-
methasone-treated rats to compare overt acute toxic responses
elicited by diamidoxime compounds 1, 5, and 7 and their cor-
responding diamidines. Compound 3 was not available in suf-
ficient quantity for evaluation of acute toxicity. Overt acute
adverse reactions following single intravenous bolus injections
were greatly reduced for the three bisbenzamidoximes com-
pared to those for the bisbenzamidines, and no adverse reac-
tions were observed after high single oral doses of the bisbenz-
amidoximes.
Normal rats injected over 30 s with 20 mmol of pentamidine
(compound 2) kg21 appeared hypotensive, with rapid paling of
extremities, hypoactivity, and dyspnea, which progressed to
slight cyanosis of extremities. Increased lacrimation and minor
hind-leg ataxia were observed immediately before the onset of
hypoactivity. Animals appeared to fully recover within 5 min.
Animals injected with pentamidine at 40 mmol kg21 had im-
mediate severe hind-limb muscular contractions, increased sal-
ivation, dyspnea, initial paling of the extremities that pro-
gressed to marked cyanosis, and profound hypoactivity, with
no movement for at least 5 min. All animals recovered approx-
imately 20 min after injection. In contrast, the diamidoxime
analog (compound 1) of pentamidine, given in the same man-
ner, caused no observable adverse reactions from 20 to 60
mmol kg21. Minor toxic responses, including barely observable
hind-leg ataxia and slight hypoactivity, were observed at 80
mmol kg21, with complete recovery within 5 min postinjection.
FIG. 1. Metabolism of bisbenzamidoximes (compound 1, 3, 5, or 7) by rat
liver homogenate 9,000 3 g supernatant fraction. Homogenates containing 167
mM diamidoxime as substrate plus cofactor solution were incubated for 30 min
at 37°C, then assayed by HPLC as described in Materials and Methods. Com-
pound structures are shown in Table 1. IS, internal standard.
FIG. 2. Time course of reduction of bisbenzamidoxime compound 1 to its
monoamidoxime-monoamidine product (compound 9) by rat liver microsomes
(F) and the postmitochondrial supernatant fraction (E). Reaction conditions
and the HPLC assay were as described for Fig. 1 and in Materials and Methods.
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Bolus injections above 120 mmol kg21 produced severe dys-
pnea and profound hypoactivity.
Similar results were observed for diamidoximes 5 and 7 com-
pared to their respective diamidine analogs (data not shown).
The diamidine compound 6 did appear less acutely toxic than
pentamidine, while the diamidine compound 8 was slightly
more acutely toxic. Finally, no overt acute toxic responses were
seen when animals were given any of the test compounds per
os, including single oral doses as high as 160 mmol kg21 for
each of the diamidoxime compounds 1, 5, and 7.
(ii) Subchronic toxicity in corticosteroid-immunosuppressed
rats. Although the bisbenzamidoxime compounds 1, 5, and 7
appear to cause less overt acute toxicity following single intra-
venous injections, the diamidoximes do retain substantial overt
toxicity in the dexamethasone-suppressed rats treated with test
compounds for 14 days. Subjective scores of multiple dosing
toxicity were assigned and are included in Table 1. Pentami-
dine given at its intravenous therapeutic dose of 22 mmol kg21
day21 has been assigned a subjective toxicity score of 11,
primarily because of its hypotensive response but also because
it can cause inflammation of the tail with multiple injections.
The four bisbenzamidoximes (compounds 1, 3, 5, and 7) tested
were assigned scores of 1 to 111 when given intravenously.
Each bisbenzamidoxime caused substantial inflammation of
the tail. The tails of most animals in each group became red-
dened and swollen after 3 to 5 days of injections; then many
became severely necrotic before the end of the 14-day exper-
iment. The response to compound 3 was particularly severe. In
addition, diamidoxime compound 7 caused deaths late in the
treatment regime. Three of six animals treated intravenously
with compound 7 at 22 mmol kg21 died late (days 11 and 12)
during treatment. Animals that died became very pale 2 to 3
days before death, and internal organs were blanched and
grossly necrotic upon necropsy. Finally, one animal treated
orally at 33 mmol kg21 day21 with diamidoxime compound 3
and one treated orally with compound 5 died during the ex-
periment. No other adverse reactions were detected in orally
treated animals, and the deaths may not have been treatment
related.
Metabolism of amidoximes. (i) Metabolism of bisbenzami-
doximes active against Pneumocystis. Data presented in Fig.
1A confirm previous observations that rat liver homogenates
reduce the diamidoxime (compound 1) of pentamidine, form-
ing the monoamidine-monoamidoxime (compound 9) and
smaller quantities of the diamidine, pentamidine (compound
2). The metabolites have previously been identified by mass
spectrometry (16, 52) and were confirmed in the present study
by coelution with authentic standards.
Three other bisbenzamidoximes (compounds 3, 5, and 7)
with good oral anti-Pneumocystis activity appear to be metab-
olized similarly. The smaller peaks in Fig. 1B through D co-
eluted exactly with the authentic diamidine standard com-
pounds 4, 6, and 8, respectively. Although synthetic standards
were not available for the monoamidine-monoamidoxime de-
rivatives of compounds 3, 5, and 7, the relative retention times
of the chromatographic peaks are entirely consistent with
those predicted for the monoamidoxime derivatives. Most
monoamidine-monoamidoxime derivatives have been difficult
to synthesize and to analyze by mass spectrometric methods
developed to characterize pentamidine metabolites (7, 16, 52).
Positive identification of these putative metabolites must await
successful development of new synthetic and analytical ap-
proaches.
Although oxidative N-hydroxylation of amidines to form
amidoximes is known to be catalyzed by specific cytochromes
P-450 (6, 22), reduction of amidoximes back to amidines has
been reported to be catalyzed by a non-cytochrome P-450-
dependent reductase activity (22). Data presented in Fig. 2 and
3 are consistent with these observations (22). First, reductase
activity was present in the postmitochondrial microsomal frac-
FIG. 3. Metabolism of the bisbenzamidoxime compound 1 by 9,000 3 g
supernatants from homogenates of rat liver, kidney, lung, and heart. Incubation
conditions were as described for Figure 1. Compound structures are shown in
Table 1.
FIG. 4. Metabolism of bisbenzamidoximes by intact BRL 3A hepatocytes in
vitro. Cells cultured in Ham’s F-12 medium containing 5% fetal bovine serum
and 10 mM diamidoxime substrate were incubated for 24 h at 37°C under 5%
CO2. The extracellular medium was extracted and assayed by HPLC as described
for Fig. 1. Compound structures are shown in Table 1.
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tion, as reported; however, activity was even higher in the
postmitochondrial supernatant fraction (Fig. 2). Second, re-
ductase activity was detected in cell extracts from liver, as
reported (22), but activity is also present in homogenates from
rat kidneys, lung, heart, and brain (Fig. 3). Finally, intact cells
of the established liver cell line BRL 3A (Fig. 4A), the heart
cell line H9c2, and the macrophage cell line J774 A.1 (data not
shown) all absorbed and metabolized the diamidoxime com-
pound 1.
Diamidoxime prodrugs effective against extracellular para-
sites, such as Pneumocystis, apparently must enter host cells
and be chemically reduced back to the active amidine, then
released extracellularly and taken up by the infectious organ-
ism. This process of cell uptake, metabolism, and release oc-
curs readily in intact BRL 3A hepatocytes cultured in vitro
(Fig. 4). Each of the bisbenzamidoximes 1, 3, 5, and 7 added to
BRL 3A cultures was metabolized predominantly to the cor-
responding diamidine, then released into the culture superna-
tants. For each chromatogram of Fig. 4, the peak labeled as a
diamidine coeluted exactly with the authentic standard of that
diamidine.
(ii) Metabolism of diamidoximes that lack anti-Pneumocystis
activity. The novel bisbenzamidoxime compounds 11 and 13,
the bisbenzimidazole diamidoximes 15 and 17, and the carba-
zole compound 19 had little or no activity orally or intrave-
nously against Pneumocystis, even though the corresponding
diamidines were very active intravenously (Table 1). Lack of
activity is not associated with inability to be metabolized in
vitro. Incubation of diamidoxime 15 with rat liver homogenates
produced two new peaks, one that coeluted with the authentic
standard for diamidine 16 and a larger peak with a relative
retention time consistent with that predicted for the corre-
sponding monoamidoxime (Fig. 5C). Similar results were ob-
tained with diamidoximes 11 (Fig. 5A), 13, 17, and 19 (data not
shown).
Preliminary data with intact cultured cells suggest that one
possible hypothesis for the absence of anti-Pneumocystis activity
may be reduced cellular uptake and metabolism of the inactive
diamidoximes. In contrast to the results presented above for the
active bisbenzamidoximes 1, 3, 5, and 7 (Fig. 4), the inactive
diamidoximes 11 (Fig. 5B) and 15 (Fig. 5D) were not readily
metabolized by intact BRL 3A hepatocytes in culture. Little or no
detectable diamidine or putative monoamidine-monoamidoxime
products were present in the culture medium.
Structural features causing diamidoximes 11, 13, 15, 17, and
19 to have reduced anti-Pneumocystis activity have not been
determined. Inactive diamidoximes have two obvious struc-
tural features that differ from those of active diamidoximes.
Inactive compounds all contain additional nitrogen atoms in
positions other than the amidoxime moieties, and they lack
ether oxygens linking the alkane chains to the aromatic rings.
The additional nitrogen atoms of inactive compounds 11 and
13 are part of the internal amide groups; reversing the order of
the CO and NH groups had no effect on activity (Table 1). The
additional nitrogens of compound 15 are part of the benzimid-
azole groups; N-methyl substitution (compound 17) did not
improve activity (Table 1). A diamidoxime from the exciting
new carbazole class of dicationic compounds (47) was also
shown to be inactive against P. carinii orally and was not me-
tabolized by intact cells. Compounds from this series contain
one additional nitrogen in the carbazole nucleus. Inactive com-
pounds 11 and 13 have oxygens in the bridge between the
benzamidoxime groups, although they are carbonyl and not
ether oxygens. Compounds 15, 17, and 19 entirely lack oxygens
in the bridge. Diamidoxime derivatives from one other class of
aromatic dications, the very promising furan series (12–14),
have recently been shown to have anti-Pneumocystis activity
orally and intravenously (13). The link between the benzami-
doxime moieties and the furan bridge of these compounds is
via carbon-carbon bonds, although an ether oxygen is present
in the furan ring of the bridge. Further research using struc-
turally diverse compounds to examine cellular transport, me-
tabolism, and subsequent release is in progress in an effort to
understand and predict why some amidoxime derivatives are
not active.
The present study thus provides additional evidence that the
amidoxime prodrug approach should work to improve oral
activity for some diamidines. The diamidoxime of pentamidine
is indeed an orally effective anti-Pneumocystis agent, and three
novel bisbenzamidoxime analogs of pentamidine were even
more effective than the pentamidine derivative. Moreover,
acute overt toxicity following single bolus intravenous injec-
tions of these bisbenzamidoximes was greatly reduced com-
pared to that of the bisbenzamidines. The bisbenzamidoximes,
however, are not likely candidates for future drug development
because the parent compounds have significant toxicity (40,
48), and they retain multiple sites subject to cytochrome P-450-
mediated oxidative metabolism. Finally, the present results
demonstrate that the diamidoxime prodrug approach will work
for some but not all classes of antimicrobially active aromatic
dications. Novel diamidoximes of two bisbenzamidines, two
bisbenzimidazole diamidines, and one carbazole diamidine
were not active against Pneumocystis intravenously or orally,
even though the parent compounds were very active. Although
all diamidoximes examined could be metabolized by tissue
homogenates, the inactive compounds were not metabolized to
the diamidines by intact cultured cells, suggesting that lack of
activity may be associated with reduced cellular uptake and
reduced subsequent metabolism by intact cells. Current efforts
to develop effective new prodrugs focus on development of
FIG. 5. Metabolism of diamidoximes that lack activity against Pneumocystis.
(A and C) Metabolism by rat liver homogenate supernatant fractions as de-
scribed for Fig. 1; (B and D) metabolism by intact BRL 3A hepatocytes as
described for Fig. 4. Compound structures are shown in Table 1.
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predictive experimental systems to evaluate uptake, metabo-
lism, and subsequent antimicrobial activity in vitro.
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